Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Friday, November 22, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a clinical stage gene editing company, has announced its participation in the upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies. This involvement underscores its active role in the industry and commitment to advancing gene editing technologies.
Price reaction · baseline $6.5 (2024-11-21 close) · hit pre-market · 7 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+11.7%
day 1
+11.4%
day 3
+9.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is actively participating in significant industry conferences.
  • The company is leveraging its proprietary ARCUS platform for gene editing therapies.
  • Participation in these conferences highlights the company's commitment to innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Oct. 21, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the

Frequently Asked Questions

What conferences will Precision BioSciences attend?

Precision BioSciences will participate in the Longwood Boston CEO and Guggenheim Healthcare Conferences.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing therapies.

What is the focus of Precision BioSciences?

Precision BioSciences focuses on developing in vivo gene editing therapies.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences ARCUS platform gene editing healthcare conferences
Last updated: Nov 22, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →